Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 1
8(80.0%)
Phase 2
1(10.0%)
Phase 3
1(10.0%)
10Total
Phase 1(8)
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT05131022Phase 1Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Role: lead

NCT07221500Phase 2Recruiting

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Role: lead

NCT07520006Phase 1Not Yet Recruiting

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Role: lead

NCT07516093Phase 3Not Yet Recruiting

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Role: lead

NCT04830137Phase 1Recruiting

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Role: lead

NCT06717269Phase 1Recruiting

Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets

Role: lead

NCT05107674Phase 1Recruiting

A Study of NX-1607 in Adults With Advanced Malignancies

Role: lead

NCT06593457Phase 1Completed

A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects

Role: lead

NCT06691828Phase 1Completed

Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948

Role: lead

NCT05107739Phase 1Terminated

A Study of DeTIL-0255 in Adults With Advanced Malignancies

Role: lead

All 10 trials loaded